Marshall Wace LLP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Marshall Wace LLP raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 254.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,968 shares of the biopharmaceutical company's stock after buying an additional 52,368 shares during the period. Marshall Wace LLP's holdings in Amicus Therapeutics were worth $687,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock worth $275,619,000 after purchasing an additional 458,143 shares during the last quarter. Wellington Management Group LLP boosted its position in Amicus Therapeutics by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock valued at $268,112,000 after buying an additional 4,497,950 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Amicus Therapeutics by 3.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,267,375 shares of the biopharmaceutical company's stock worth $30,779,000 after acquiring an additional 107,348 shares during the last quarter. Norges Bank bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $29,033,000. Finally, Renaissance Technologies LLC raised its stake in shares of Amicus Therapeutics by 174.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock valued at $19,863,000 after acquiring an additional 1,339,316 shares during the last quarter.

Amicus Therapeutics Stock Down 0.1 %

Shares of Amicus Therapeutics stock traded down $0.01 during midday trading on Friday, hitting $6.67. The company had a trading volume of 6,371,892 shares, compared to its average volume of 2,692,364. Amicus Therapeutics, Inc. has a 52-week low of $6.20 and a 52-week high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock has a market capitalization of $2.05 billion, a P/E ratio of -37.06, a P/E/G ratio of 1.51 and a beta of 0.79. The company has a 50 day moving average of $7.95 and a 200 day moving average of $9.27.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group reduced their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. UBS Group increased their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Wells Fargo & Company cut their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.